Atty Dkt. No.: AREN-005CON

USSN: 10/668,035

AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph beginning on page 1, line 3 (the first paragraph following the Title), with the following rewritten paragraph:

This Application is a continuation of U.S. Application No. 09/364,425, filed July 30, 1999, now U.S. Patent No. 6, 653, 086, which is a continuation-in-part of U.S. Application No. 09/060,188, filed April 14, 1998. This Application claims the The benefit of commonly owned: (1) U.S. Provisional Patent Application Serial No. 60/094,879, filed Jul. 31, 1998; (2) U.S. Provisional Patent Application Serial No. 60/106,300, filed Oct. 30, 1998; (3) U.S. Provisional Patent Application Serial No. 60/110,906, filed Dec. 4, 1998, and (4) U.S. Provisional Application Serial No. 60/121,851, filed Feb. 26, 1999 is hereby claimed. This patent document is related to U.S. Ser. No. 09/060,188, filed Apr. 14, 1998. The entire disclosures of each of the foregoing patent applications are incorporated herein by reference.

On page 6, please replace the paragraph beginning with "Figure 12" with the following rewritten paragraph:

Figure 12 is a copy of an autoradiograph Figures 12A-D are copies of autoradiographs evidencing the results from in situ hybridization (normal rat) using GPR6 probe (12A), and orexin 1 receptor probe (12B) with overlays for determination of co-localization of the two receptors (12C and 12D).

On page 6, please replace the paragraph beginning with "Figure 13" with the following rewritten paragraph:

Figure 13 is a copy of an autoradiograph Figures 13A-D are copies of autoradiographs evidencing the results from in situ hybridization (normal rat) using GPR6 probe (13A), and melanocortin-3 receptor probe (13B) with overlays for determination of co-localization of the two receptors (13C and 13D).

Atty Dkt. No.: AREN-005CON USSN: 10/668,035

On page 7, please replace the paragraph beginning with "Figure 18A-L" with the following rewritten paragraph:

Figure 18A-L is Figures 18A-L provide a sequence diagram of the preferred vector pCMV, including restriction enzyme site locations. Nucleotide sequences are set forth as SEQ ID NOs: 52 and 53, and amino acid sequences are set forth as SEQ ID NOs: 54 through 59 (from top to bottom).

On page 26, please replace the paragraph beginning with "With respect to GPR4" with the following rewritten paragraph.

With respect to GPR4 (GenBank accession number L36148 (**SEQ ID NO:60**)), expression vectors comprising the cDNA was generously supplied by Brian O'Dowd (University of Toronto). The vector for GPR4 cDNA was pcDNA3 and this <u>was</u> subcloned into pCMV vector at a Hind III-XbaI site (the 5' untranslated region between HindIII and an ApaI site was trimmed by conducting digestion/self ligation).